Skip to main content
PMC home page
Bulletin of the World Health Organization logoLink to Bulletin of the World Health Organization
. 1995;73(4):523–527.

Long-term immunogenicity and efficacy of a reduced dose of plasma-based hepatitis B vaccine in young adults.

K T Goh 1, C J Oon 1, B H Heng 1, G K Lim 1
PMCID: PMC2486776  PMID: 7554025

Abstract

A cohort of seronegative preclinical medical and dental students and another cohort of seronegative national service recruits who were immunized intramuscularly with a reduced dose (10 micrograms) of plasma-based hepatitis B vaccine (Merck, Sharp & Dohme) at the start of the study and at 1 month and 6 months thereafter were followed up for 5 years and 6 years, respectively. Among the medical and dental students, antibody to hepatitis B surface antigen (anti-HBs) ( > or = 10 mlU/ml) was detected in 81% of the vaccinees at the end of the 5-year follow-up and the geometric mean titre (GMT) had dropped from 412.6 mlU/ml one year after completion of vaccination to 174.9 mlU/ml after 5 years. Antibody to hepatitis B core antigen (anti-HBc) was detected in 0.4-1.0% of the vaccinees but none was positive for hepatitis B surface antigen (HBsAg) during the follow-up period. Among the national servicemen, the anti-HBs seroconversion rate and GMT were considerably lower than those of the preclinical medical and dental students. At the end of the 6-year follow-up, 55% of the vaccinees were positive for anti-HBs ( > or = 10 mlU/ml) and the GMT had dropped from 80.7 mlU/ml one year after completion of vaccination to 30.4 mlU/ml after 6 years. Anti-HBc was detected in 8 (2.7%) and transient HBs antigenaemia in 2 (0.7%) of 293 vaccinees after 4 years.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
525

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ayoola E. A. The immune response of healthy Nigerian adults to small doses of hepatitis B vaccine: comparison of 10- and 20-micrograms doses. J Med Virol. 1984;13(3):223–225. doi: 10.1002/jmv.1890130304. [DOI] [PubMed] [Google Scholar]
  2. Coursaget P., Yvonnet B., Chotard J., Sarr M., Vincelot P., N'doye R., Diop-Mar I., Chiron J. P. Seven-year study of hepatitis B vaccine efficacy in infants from an endemic area (Senegal). Lancet. 1986 Nov 15;2(8516):1143–1145. doi: 10.1016/s0140-6736(86)90543-x. [DOI] [PubMed] [Google Scholar]
  3. Davidson M., Krugman S. Recombinant yeast hepatitis B vaccine compared with plasma-derived vaccine: immunogenicity and effect of a booster dose. J Infect. 1986 Jul;13 (Suppl A):31–38. doi: 10.1016/s0163-4453(86)92653-8. [DOI] [PubMed] [Google Scholar]
  4. Deinhardt F. Aspects of vaccination against hepatitis B; passive-active immunization schedules and vaccination responses in different age groups. Scand J Infect Dis Suppl. 1983;38:17–23. [PubMed] [Google Scholar]
  5. Goh K. T., Chan Y. W., Wong L. Y., Kong K. H., Oon C. J., Guan R. The prevalence of hepatitis B virus markers in dental personnel in Singapore. Trans R Soc Trop Med Hyg. 1988;82(6):908–910. doi: 10.1016/0035-9203(88)90038-7. [DOI] [PubMed] [Google Scholar]
  6. Goh K. T., Doraisingham S., Tan K. L., Oon C. J., Ho M. L., Chen A. J., Chan S. H. The hepatitis B immunization programme in Singapore. Bull World Health Organ. 1989;67(1):65–70. [PMC free article] [PubMed] [Google Scholar]
  7. Goudeau A., Dubois F., Dubois M. C., Louq C., Mazert M. C. Immunogenicity of low dose (1.25 and 0.31 micrograms) hepatitis B vaccine. Lancet. 1984 Nov 10;2(8411):1091–1092. doi: 10.1016/s0140-6736(84)91524-1. [DOI] [PubMed] [Google Scholar]
  8. Guan R., Tay H. H., Yap I., Smith R., Tan L. H. Immunogenicity of a low dose recombinant DNA hepatitis B vaccine in healthy adults in Singapore. Asian Pac J Allergy Immunol. 1989 Dec;7(2):85–88. [PubMed] [Google Scholar]
  9. Guan R., Tay H. H., Yap I., Smith R., Tan L. H. The immune response of low dose recombinant DNA hepatitis B vaccine in teenagers in Singapore. Trans R Soc Trop Med Hyg. 1990 Sep-Oct;84(5):731–732. doi: 10.1016/0035-9203(90)90167-d. [DOI] [PubMed] [Google Scholar]
  10. Hadler S. C., Francis D. P., Maynard J. E., Thompson S. E., Judson F. N., Echenberg D. F., Ostrow D. G., O'Malley P. M., Penley K. A., Altman N. L. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med. 1986 Jul 24;315(4):209–214. doi: 10.1056/NEJM198607243150401. [DOI] [PubMed] [Google Scholar]
  11. Kane M. Reduced doses of hepatitis B vaccines: is it a good idea? Bull World Health Organ. 1995;73(4):529–530. [PMC free article] [PubMed] [Google Scholar]
  12. Lelie P. N., Reesink H. W., de Jong-van Manen S. T., Dees P. J., Reerink-Brongers E. E. Immunogenicity and safety of a plasma-derived heat-inactivated hepatitis B vaccine (CLB). Studies in volunteers at a low risk of infection with hepatitis B virus. Am J Epidemiol. 1984 Nov;120(5):694–702. doi: 10.1093/oxfordjournals.aje.a113936. [DOI] [PubMed] [Google Scholar]
  13. Ljunggren K., Löfgren B., Nordenfelt E. Varying antibody response in hospital staff vaccinated against hepatitis B. Scand J Infect Dis. 1988;20(5):485–488. doi: 10.3109/00365548809032495. [DOI] [PubMed] [Google Scholar]
  14. Matsaniotis N., Kattamis C., Dionyssopouolou E., Laskari S. Immunogenicity of low doses of hepatitis B vaccine in normal children. Vaccine. 1985 Sep;3(3):297–299. doi: 10.1016/s0264-410x(85)90098-2. [DOI] [PubMed] [Google Scholar]
  15. Milne A., Moyes C. D., Allwood G. K., Pearce N. E., Krugman S. Antibody responses to recombinant, yeast-derived hepatitis B vaccine in teenage New Zealand children. N Z Med J. 1988 Feb 24;101(840):67–69. [PubMed] [Google Scholar]
  16. Moyes C. D., Milne A., Dimitrakakis M., Goldwater P. N., Pearce N. Very-low-dose hepatitis B vaccine in newborn infants: an economic option for control in endemic areas. Lancet. 1987 Jan 3;1(8523):29–31. doi: 10.1016/s0140-6736(87)90712-4. [DOI] [PubMed] [Google Scholar]
  17. Oon C. J., Tan K. L., Goh K. T., Wong-Yong L., Viegas O., McCarthy T., Chan S. H., Lee H. P. Evaluation of a low dose of hepatitis B vaccine given within a childhood immunisation programme in Singapore. J Infect. 1986 Nov;13(3):255–267. doi: 10.1016/s0163-4453(86)91223-5. [DOI] [PubMed] [Google Scholar]
  18. Papaevangelou G., Roumeliotou-Karayannis A., Vissoulis C., Richardson S. C., Krugman S. Immunogenicity of a five-microgram dose of hepatitis B vaccine. J Med Virol. 1985 Jan;15(1):65–69. doi: 10.1002/jmv.1890150109. [DOI] [PubMed] [Google Scholar]
  19. Papaevangelou G., Roumeliotou-Karayannis A., Vissoulis C., Stathopoulou P., Kolaitis N., Krugman S. Reduction of the dose of hepatitis B vaccine. J Infect. 1983 Jul;7 (Suppl 1):69–70. doi: 10.1016/s0163-4453(83)96718-x. [DOI] [PubMed] [Google Scholar]
  20. Papaevangelou G., Roumeliotou-Karayannis A., Vissoulis C., Stathopoulou P., Kolaitis N., Krugman S. Safety and immunogenicity of a further reduced dose (10 mcg) of the hepatitis B vaccine. Dev Biol Stand. 1983;54:209–215. [PubMed] [Google Scholar]

Articles from Bulletin of the World Health Organization are provided here courtesy of World Health Organization

RESOURCES